ERICA CAMPBELL: Open Payments
NPI 1407418650 · BRADENTON, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,977 in 149 payments from 13 companies in 2025. Trend: 2023 $631 · 2024 $2,843 · 2025 $2,977
Food & beverage: $2,977
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 23 | $491 |
| Neurocrine BioSciences, Inc. | 21 | $378 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $366 |
| Axsome Therapeutics, Inc. | 16 | $350 |
| ABBVIE INC. | 14 | $298 |
| Otsuka America Pharmaceutical, Inc. | 17 | $293 |
| E.R. Squibb & Sons, L.L.C. | 11 | $266 |
| Teva Pharmaceuticals USA, Inc. | 8 | $154 |
| Braeburn Inc. | 5 | $114 |
| Vanda Pharmaceuticals Inc. | 4 | $111 |
Products named: INGREZZA, CAPLYTA, Auvelity, ARISTADA, VRAYLAR, COBENFY, REXULTI, AUSTEDO XR.
Industry payments across FL — which companies pay providers there.
